Close Close
Popular Financial Topics Discover relevant content from across the suite of ALM legal publications From the Industry More content from ThinkAdvisor and select sponsors Investment Advisor Issue Gallery Read digital editions of Investment Advisor Magazine Tax Facts Get clear, current, and reliable answers to pressing tax questions
Luminaries Awards
ThinkAdvisor
Casket

Life Health > Life Insurance

Executives Brief Wall Street on Death

X
Your article was successfully shared with the contacts you provided.

What You Need to Know

  • Reinsurance Group of America sees death still about 3% higher than in 2019.
  • That could mean about 90,000 extra U.S. deaths this year.
  • Problems with forecasting mortality linger and could affect financial plans based on life expectancy assumptions.

The U.S. mortality rate is falling, and life insurers can handle it, but it’s still noticeably higher than it was in 2019, before COVID-19 came to light.

The excess mortality level continues to be high enough that life insurers and reinsurers think about it when pricing coverage.

“I think we’re at about 3% to 4% excess relative to pre-pandemic levels for the first half of this year,” Jonathan Porter, the chief risk officer at Reinsurance Group of America, said Aug. 2, during a conference call the Chesterfield, Missouri-based company held to go over second-quarter earnings with securities analysts.

RGA is a reinsurer, or insurance company for insurance companies. It protects life and annuity issuers against catastrophic mortality risk and other forms of risk, such as pension plan and annuity longevity risk.

About 2.8 million people died in the United States in 2019. If the U.S. excess mortality rate stays at 3% to 4% for a full year, that would imply that the country would experience about 84,000 to 112,000 extra deaths.

The chief financial officer at Globe Life talked about the lingering high mortality rate during a conference call the company held in July to go over second-quarter earnings. The Globe Life CFO gave no numbers.

Executives who have talked the most about excess mortality have noted that it’s falling, and that it’s with the limits they had used in planning. It’s no longer hurting life insurers’ earnings.

RGA, for example, reported $204 million in net income on $4.9 billion in revenue for the latest quarter, compared with $207 million in net income on $4.2 billion in revenue for the second quarter of 2023.

RGA’s adjusted operating income before income taxes, which excludes the effects of fluctuations in the value of its assets and benefits, increased to $491 million, from $736 million.

But, in some cases, it might be pushing up premiums or making executives less eager to reduce premiums.

Two kidney dialysis companies, DaVita and Fresenius, serve people who are especially vulnerable to COVID, flu and the effects of health care system strain. They are seeing the increase in mortality affecting patient volume.

Joel Ackerman, the chief financial officer of DaVita, estimated during a conference call Tuesday that the lingering excess mortality was severe enough to cut average daily dialysis patient volume by about 0.5 percentage points to 1 percentage point.

“Mortality is just running higher than it was,” Ackerman said. “It’s actually up this year relative to where it was six months ago.

Fresenius CEO Helen Giza said the mortality rate for her company’s patients is about 0.6 percentage points higher than expected.

Fresenius had hoped to achieve U.S. volume growth of 0.5% to 2% this year. The company’s new volume growth forecast is flat to 0.5%.

What it means: Problems with forecasting mortality and life expectancy linger.

Financial professionals may still want to provide extra projections and warnings about uncertainty in any arrangements that depend on life expectancy assumptions.

Credit: Kzenon/Shutterstock


NOT FOR REPRINT

© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.